Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

摘要: The aim of this study was to investigate the efficacy and toxicity docetaxel-based chemotherapy, pretreatment factors that can predict overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). From June 2005 July 2010, 70 CRPC underwent chemotherapy at Wakayama Medical University related hospitals. Docetaxel given a dose 70 mg/m2 once every 3 weeks or 35 mg/m2 twice 3 weeks. Oral estramustine 560 mg concurrently for five consecutive days during weeks 1 2 each cycle, prednisolone 10 mg day. Dexamethasone 8 mg premedicated intravenously before docetaxel administration. received median four cycles treatment (range 1–31). In serum prostate-specific antigen response, 13 (18.6 %) achieved complete response 29 (41.4 %) partial response. Median OS time progression were 14 months 6 months, respectively. follow-up period 9.5 months. Two independent risk predicted visceral metastasis including lymph node anemia. Grade 3/4 neutropenia anemia occurred 25.7 8.6 % patients, Four treatment-related deaths seen observation period. combination docetaxel, effective Japanese CRPC; however, therapy should be carefully indicated elderly and/or poor performance status due its toxicity. Visceral identified as which could OS.